Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and b) 1000-count bottles (NDC 0378-1805-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Superpotent Drug and Subpotent Drug: potency failures obtained

Recall #: D-0125-2025
Affected scope: 63,077 bottles
Initiated: November 18, 2024

Compiled from official public sources by the publisher. · Updated September 2026

Viatris Inc recalled Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-… - a moderate-severity action.

Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-… was recalled by Viatris Inc in December 18, 2024. Reason: Superpotent Drug and Subpotent Drug: potency failures obtained. Check the official notice for the remedy. Verify recall #D-0125-2025 with the FDA Drug before acting.

The recall

Viatris Inc issued this moderate-severity FDA Drug recall-Superpotent Drug and Subpotent Drug: potency failures obtained.

Moderate
severity level: Class II
classification: December 18, 2024
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0125-2025 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and b) 1000-count bottles (NDC 0378-1805-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Reason for recall

Superpotent Drug and Subpotent Drug: potency failures obtained

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Ongoing
Recall number	D-0125-2025
Date reported	December 18, 2024
Date initiated	November 18, 2024
Recalling firm	Viatris Inc
Firm location	Canonsburg, PA
Affected scope	63,077 bottles
Distribution	Nationwide within the United States and Puerto Rico

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0125-2025) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Superpotent Drug and Subpotent Drug: potency failures obtained

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on December 18, 2024. Severity: Moderate. Recall number: D-0125-2025.

Where was the recalled product distributed? ▼

Distribution: Nationwide within the United States and Puerto Rico.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

CHEVROLET 2025: FORWARD COLLISION AVOIDAN… 2024-12-18 Timolol Maleate Ophthalmic Solution USP, … 2024-12-18 Kirkland Severe Cold & Flu Plus Congestio… 2024-12-18 Hylenex recombinant (hyaluronidase) injec… 2024-12-18

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Varithena (polidocanol injectable foam) A… 2024-12-18 Dabigatran Etexilate, 75 mg capsules, 60-… 2024-12-18 Dabigatran Etexilate, 150mg capsules, 60-… 2024-12-18 Levothyroxine Sodium Tablets, USP, 100 mc… 2024-12-18

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported December 18, 2024. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026